Bayer's Nexavar Promising for Liver Cancer
Posted on: Monday, 4 June 2007, 12:00 CDT
Bayer's Nexavar improved survival of liver cancer patients in a phase 3 trial presented at the American Society of Clinical Oncology meeting in Chicago.
Nexavar, which Bayer is developing with Onyx, extended survival of primary liver cancer patients by 44 percent compared to those taking placebo.
The companies said they are now preparing applications to the Food and Drug Administration and European regulators for a supplement indication for Nexavar, which is currently approved for treating advanced kidney cancer.
These results represent an unprecedented achievement and Nexavar could become the first widely approved new therapy for this difficult to treat cancer, Jordi Bruix, co-principal investigator of the phase 3 trial and director of the Barcelona clinic liver cancer group at the hospital clinic of Barcelona, said in a statement issued by Bayer.
In the study, which is known as the SHARP trial, 602 liver cancer patients received Nexavar or placebo. Median overall survival in the Nexavar group was 10.7 months compared to 7.9 months in the placebo arm. No significant differences in serious adverse event rates were detected between the two groups.
Source: United Press International
Related Articles
- Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy
- Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
- Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
- Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
- Nexavar Shown to Significantly Extend Survival for Patients With Advanced Liver Cancer
- Results Show XELOX (Xeloda(R) Plus Oxaliplatin) Provides Equivalent Overall Patient Survival Compared to FOLFOX in Advanced Colorectal Cancer
- Updated Overall Survival Analysis Presented on Nexavar Phase III Trial
- Update on Dose-Escalation Trial of TNFerade in Pancreatic Cancer Shows Dose-Dependent Improvements in Tumor Shrinkage and Resectability and Patient Survival
- National Cancer Institute Halts Drug Trial
- Australian Cancer Technology Reports Doubling of Mean Survival Time in Patients With Pancreatic Cancer Using RP101 With Chemotherapy Treatment
 |
 |
User Comments (0)
RSS Feeds